RxDoctor Payments Data

Denise Elliott, DPM

Foot & Ankle Surgery · Marrero, LANPI 1730152760

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (53.9%), travel and lodging and education — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Stryker at 34.5% of the total.

$11,006in general payments, 2019–2025

Across 181 payments — averaging $60.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$4K
  • Organogenesis Inc.$2K
  • ALON Medical Technology$2K
  • Medical Device Business Services, Inc.$1K
  • International Life Sciences$611
  • Amgen$207
  • plus $2K from 30 others

What the payments were for

  • Travel & lodging$3,59033%
  • Food & beverage$5,93554%
  • Education$1,48113%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,006 in reported general payments places this provider in the 85th percentile of 92 foot & ankle surgery providers in Louisiana.

See all foot & ankle surgery providers in Louisiana

Medicare billing

Part B allowed, 2024
$97,190
Medicare patients
243
Services billed
1,209

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
QutenzaCapsaicin/Skin Cleanser16$58,334
JubliaEfinaconazole12$12,883
SantylCollagenase Clostridium Hist.20$7,625
Ammonium Lactate206$5,891
Ciclopirox96$4,200
Naftifine Hcl12$1,343
Mupirocin87$774
CiclopiroxCiclopirox Olamine21$593
Gabapentin50$552
Terbinafine Hcl34$528
Pregabalin15$426
Celecoxib23$334
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen26$238
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav24$235
Allopurinol14$168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GRT US Holding, Inc.Qutenza$134$58,33416 claims
Smith+NephewSantyl$73$7,62520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 92 foot & ankle surgery providers in Louisiana.

Other foot & ankle surgery in Marrero

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →